Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
View Patent ↗This invention provides a method for treating Parkinson's disease (PD), particularly early stage of PD by orally administering to a mammal sporoderm-broken germination activated Ganoderma lucidum spore powders (GASP) to reduce and/or release the symptom of rotatory behavior in PD, to reduce the progression of neuron apoptosis and to improve the tyrosine hydroxylase (TH) activity so as to increase the conversion of hydroxydopamine (DOPA) to dopamine in the dopaminergic neurons. This invention also provides a method for reducing neuron apoptosis and a method for improving TH activity in dopaminergic neurons by orally administering to a mammal GASP.
1. A method for treating Parkinson's disease comprising administering to a mammal in need thereof an effective amount of sporoderm-broken germination activated Ganoderma lucidum spores (GASP);
wherein said sporoderm-broken GASP are produced by soaking Ganoderma lucidum spores in a solution which is selected from the group consisting of water, saline, and a nutritional solution to cause to produce germinated Ganoderma lucidum spores;
placing said germinated Ganoderma lucidum spores in a culture box to activate said germinated spores at relative humidity of 65-98% and temperature of 18-48° C. to produce germination-activated Ganoderma lucidum spores so as to enhance production of bioactive substances in said germination activated Ganoderma luidum spores; and
treating said germination activated Ganoderma luidum spores with an enzyme with cell wall dissolving property and/or a mechanical means to produce said sporoderm-broken GASP.
2. The method according to claim 1 , wherein said mammal is a human.
3. The method according to claim 1 , wherein said Parkinson's disease is at an early stage.
4. The method according to claim 1 , wherein said effective amount is about 0.5 to 15 g per kg per day.
5. The method according to claim 1 , wherein said effective amount is about 1 and 8 g per kg per day.
6. The method according to claim 1 , wherein said sporoderm-broken GASP is orally administered to said mammal.
7. The method according to claim 1 , wherein said sporoderm-broken GASP reduces symptom of rotatary behavior.
8. The method according to claim 1 , wherein said sporoderm-broken GASP reduces progression of neuron apoptosis in substantia nigra.
9. The method according to claim 1 , wherein said sporoderm-broken GASP improves tyrosine hydroxylase activity in neurons.
10. The method according to claim 9 , wherein said sporoderm-broken GASP improves dopamine production in neurons.
11. A method for protecting dopaminergic neurons from neuron apoptosis in a mammal comprising in need thereof administering to said mammal an effective amount of germination activated sporoderm-broken germination activated Ganoderma luidum spores (GASP);
wherein said sporoderm-broken GASP are produced by soaking Ganoderma lucidum spores in a solution which is selected from the group consisting of water, saline, and a nutritional solution to cause to produce germinated Ganoderma luidum spores;
placing said germinated Ganoderma luidum spores in a culture box to activate said germinated spores at relative humidity of 65-98% and temperature of 18-48° C. to produce germination-activated Ganoderma luidum spores so as to enhance production of bioactive substances in said germination activated Ganoderma luidum spores; and
treating said germination activated Ganoderma luidum spores with an enzyme with cell wall dissolving property and/or a mechanical means to produce said sporoderm-broken GASP.
12. The method according to claim 11 , wherein said mammal is a human.
13. The method according to claim 11 , wherein said sporoderm-broken GASP is orally administered to said mammal.
14. The method according to claim 11 , wherein said sporoderm-broken GASP increases tyrosine hydroxylase activity in said dopaminergic neurons.
15. The method according to claim 14 , wherein said sporoderm-broken GASP increases dopamine production in said dopaminergic neurons.
16. A method for increasing tyrosine hydroxylase activity in dopaminergic neurons of a mammal comprising in need thereof administering to said mammal an effective amount of sporoderm-broken germination activated Ganoderma lucidum spores (GASP);
wherein said sporoderm-broken GASP are produced by soaking Ganoderma lucidum spores in a solution which is selected from the group consisting of water, saline, and a nutritional solution to cause to produce germinated Ganoderma luidum spores;
placing said germinated Ganoderma luidum spores in a culture box to activate said germinated spores at relative humidity of 65-98% and temperature of 18-48° C. to produce germination-activated Ganoderma luidum spores so as to enhance production of bioactive substances in said germination activated Ganoderma luidum spores and
treating said germination activated Ganoderma luidum spores with an enzyme with cell wall dissolving property and/or a mechanical means to produce said sporoderm-broken GASP.
17. The method according to claim 16 , wherein said mammal is a human.
18. The method according to claim 16 , wherein said sporoderm-broken GASP is orally administered to said mammal.
19. The method according to claim 16 , wherein said sporoderm-broken GASP increases conversion of hydroxydopamine to dopamine.
20. The method according to claim 1 , wherein said enzyme with cell wall dissolving property is chihinase or cellulose.
21. The method according to claim 1 , wherein said mechanical means is micronization, roll pressing, grinding, or super high pressure microstream.